BR9809071A - Agentes farmacológicos - Google Patents

Agentes farmacológicos

Info

Publication number
BR9809071A
BR9809071A BR9809071-2A BR9809071A BR9809071A BR 9809071 A BR9809071 A BR 9809071A BR 9809071 A BR9809071 A BR 9809071A BR 9809071 A BR9809071 A BR 9809071A
Authority
BR
Brazil
Prior art keywords
pharmacological agents
selective
antagonists
glur5 receptor
pain
Prior art date
Application number
BR9809071-2A
Other languages
English (en)
Inventor
David Bleakman
David R Helton
Smriti Iyengar
David Lodge
Paul L Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9809071A publication Critical patent/BR9809071A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"AGENTES FARMACOLóGICOS"<D>. Antagonistas seletivos para o receptor de GluR5 são úteis no tratamento de dor. Também são apresentados novos derivados de decaidroisoquinolina que são antagonistas seletivos do receptor de GluR5.
BR9809071-2A 1997-04-07 1998-04-06 Agentes farmacológicos BR9809071A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (en) 1997-04-07 1998-04-06 Pharmacological agents

Publications (1)

Publication Number Publication Date
BR9809071A true BR9809071A (pt) 2000-08-01

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809071-2A BR9809071A (pt) 1997-04-07 1998-04-06 Agentes farmacológicos

Country Status (17)

Country Link
US (1) US6242462B1 (pt)
EP (1) EP0980358A4 (pt)
JP (1) JP2001521505A (pt)
KR (1) KR20010006075A (pt)
CN (1) CN1259126A (pt)
AU (1) AU734657B2 (pt)
BR (1) BR9809071A (pt)
CA (1) CA2285192A1 (pt)
EA (1) EA199900912A1 (pt)
HU (1) HUP0002030A3 (pt)
ID (1) ID23013A (pt)
IL (1) IL132086A0 (pt)
NO (1) NO994850L (pt)
NZ (1) NZ337827A (pt)
PL (1) PL336068A1 (pt)
TR (1) TR199902449T2 (pt)
WO (1) WO1998045270A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240299T1 (de) 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure
DK1200073T3 (da) * 1999-07-06 2007-05-07 Lilly Co Eli Selektive iGluR5-receptorantagonister til behandling af migræne
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
JP4132049B2 (ja) * 2001-01-05 2008-08-13 イーライ リリー アンド カンパニー 興奮性アミノ酸レセプターアンタゴニスト
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6953805B2 (en) 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7488756B2 (en) * 2001-01-23 2009-02-10 Neurosearch A/S Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds
WO2003091243A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
US7795266B2 (en) * 2003-09-25 2010-09-14 Helton David R Tetrahydroindolone derivatives for treament of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
EP2578216A1 (en) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor

Also Published As

Publication number Publication date
JP2001521505A (ja) 2001-11-06
NO994850D0 (no) 1999-10-05
WO1998045270A1 (en) 1998-10-15
NO994850L (no) 1999-10-05
CN1259126A (zh) 2000-07-05
CA2285192A1 (en) 1998-10-15
TR199902449T2 (xx) 2000-07-21
EA199900912A1 (ru) 2000-04-24
EP0980358A4 (en) 2001-02-07
NZ337827A (en) 2000-12-22
AU734657B2 (en) 2001-06-21
HUP0002030A3 (en) 2002-01-28
HUP0002030A2 (hu) 2001-04-28
PL336068A1 (en) 2000-06-05
AU6955598A (en) 1998-10-30
US6242462B1 (en) 2001-06-05
IL132086A0 (en) 2001-03-19
EP0980358A1 (en) 2000-02-23
ID23013A (id) 1999-12-30
KR20010006075A (ko) 2001-01-15

Similar Documents

Publication Publication Date Title
BR9809071A (pt) Agentes farmacológicos
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
FI952064A0 (fi) Takykiniinireseptoriantagonisteja, joilla ei ole peptidyylirakennetta
BR9916857A (pt) 4 heteroaril diarilaminas
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
NO20003550D0 (no) Farmasøytiske sammensetninger og anvendelse herav
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE235467T1 (de) Antagonisten des vitronectin-rezeptors
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
MA24736A1 (fr) Indoles 2,3-substitues servant d&#39;agents anti-inflammatoires et analgesiques
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
ID19245A (id) Antagonis reseptor vitronektin, pembuatannya dan pemakaiannya
YU13301A (sh) Muskarinski agonisti i antagonisti
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell&#39;etilene.
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.